Cost effectiveness of mammography screening for Chinese women
Authors:
- Karen M. KuntzKKKaren M. Kuntz
- Benjamin J. CowlingBCBenjamin J. Cowling
- Gabriel M. LeungGLGabriel M. Leung
Open Access
Abstract
BACKGROUND. Although the cost effectiveness of screening mammography in most western developed populations has been accepted, it may not apply to Chinese women, who have a much lower breast cancer incidence. The authors estimated the cost effectiveness of biennial mammography in Hong Kong Chinese women to inform evidence-based screening policies. METHODS. For the current study, a state-transition Markov model was developed to simulate mammography screening, breast cancer diagnosis, and treatment in a hypothetical cohort of Chinese women. The benefit of mammography was modeled by assuming a stage shift, in which cancers in screened women were more likely to be diagnosed at an earlier disease stage. The authors compared costs, quality-adjusted life years (QALYs) saved, and life years saved (LYS) for 5 screening strategies. RESULTS. Biennial screening resulted in a gain in life expectancy ranging from 4.3 days to 9.4 days compared with no screening at an incremental cost of from US$1166 to US$2425 per woman. The least costly, nondominated screening option was screening from ages 40 years to 69 years, with an incremental cost-effectiveness ratio (ICER) of US$61,600 per QALY saved or US$64,400 per LYS compared with no screening. In probabilistic sensitivity analyses, the probability of the ICER being below a threshold of US$50,000 per QALY (LYS) was 15.3% (14.6%). CONCLUSIONS. The current results suggested that mammography for Hong Kong Chinese women currently may not be cost effective based on the arbitrary threshold of US$50,000 per QALY. However, clinicians must remain vigilant and periodically should revisit the question of population screening: Disease rates in China have been increasing because of westernization and socioeconomic development. Cancer 2007. © 2007 American Cancer Society.Keywords
This publication has 38 references indexed in Scilit:
- Effect of Screening and Adjuvant Therapy on Mortality from Breast CancerNew England Journal of Medicine, 2005
- The Cost-Effectiveness of Screening Programs Using Single and Multiple Birth Cohort Simulations: A Comparison Using a Model of Cervical CancerMedical Decision Making, 2004
- Benefits and Costs of Interventions to Improve Breast Cancer Outcomes in African American WomenJournal of Clinical Oncology, 2004
- On the efficacy of screening for breast cancerInternational Journal of Epidemiology, 2004
- Does NICE have a cost‐effectiveness threshold and what other factors influence its decisions? A binary choice analysisHealth Economics, 2004
- Screening for breast cancer with mammographyThe Lancet, 2001
- Cost-Effectiveness Analysis and the Consistency of Decision MakingPharmacoEconomics, 2001
- Representing Both First- and Second-order Uncertainties by Monte Carlo Simulation for Groups of PatientsMedical Decision Making, 2000
- 14 years of follow-up from the Edinburgh randomised trial of breast-cancer screeningThe Lancet, 1999
- EVALUATING THE COST-EFFECTIVENESS OF CLINICAL AND PUBLIC HEALTH MEASURESAnnual Review of Public Health, 1998